GB201205752D0 - Treatment - Google Patents

Treatment

Info

Publication number
GB201205752D0
GB201205752D0 GB201205752A GB201205752A GB201205752D0 GB 201205752 D0 GB201205752 D0 GB 201205752D0 GB 201205752 A GB201205752 A GB 201205752A GB 201205752 A GB201205752 A GB 201205752A GB 201205752 D0 GB201205752 D0 GB 201205752D0
Authority
GB
United Kingdom
Prior art keywords
hours
plasma concentration
mumu
alkyl
period
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB201205752A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cyclacel Ltd
Original Assignee
Cyclacel Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyclacel Ltd filed Critical Cyclacel Ltd
Priority to GB201205752A priority Critical patent/GB201205752D0/en
Publication of GB201205752D0 publication Critical patent/GB201205752D0/en
Priority to US14/387,963 priority patent/US20150320762A1/en
Priority to JP2015502453A priority patent/JP2015514703A/ja
Priority to PCT/GB2013/050816 priority patent/WO2013144632A1/en
Priority to EP13714992.8A priority patent/EP2833865A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GB201205752A 2012-03-30 2012-03-30 Treatment Ceased GB201205752D0 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
GB201205752A GB201205752D0 (en) 2012-03-30 2012-03-30 Treatment
US14/387,963 US20150320762A1 (en) 2012-03-30 2013-03-28 Treatment of proliferative diseases with pyrimidodiazepinones
JP2015502453A JP2015514703A (ja) 2012-03-30 2013-03-28 ピリミドジアゼピノンを用いた増殖性疾患の治療
PCT/GB2013/050816 WO2013144632A1 (en) 2012-03-30 2013-03-28 Treatment of proliferative diseases with pyrimidodiazepinones
EP13714992.8A EP2833865A1 (en) 2012-03-30 2013-03-28 Treatment of proliferative diseases with pyrimidodiazepinones

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201205752A GB201205752D0 (en) 2012-03-30 2012-03-30 Treatment

Publications (1)

Publication Number Publication Date
GB201205752D0 true GB201205752D0 (en) 2012-05-16

Family

ID=46160090

Family Applications (1)

Application Number Title Priority Date Filing Date
GB201205752A Ceased GB201205752D0 (en) 2012-03-30 2012-03-30 Treatment

Country Status (5)

Country Link
US (1) US20150320762A1 (https=)
EP (1) EP2833865A1 (https=)
JP (1) JP2015514703A (https=)
GB (1) GB201205752D0 (https=)
WO (1) WO2013144632A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2205603T3 (pl) 2007-09-28 2014-07-31 Cyclacel Ltd Pochodne pirymidyny jako inhibitory kinaz białkowych
WO2014145909A2 (en) 2013-03-15 2014-09-18 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone compounds and methods of treating disorders
KR20220047822A (ko) * 2019-08-16 2022-04-19 싸이클라셀 리미티드 피리미디노 디아제핀 유도체의 결정질 형태

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0302220D0 (en) 2003-01-30 2003-03-05 Cyclacel Ltd Use
TW200808325A (en) * 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds
GB0718608D0 (en) 2007-09-24 2007-10-31 Tyco Electronics Raychem Nv Cable termination
PL2205603T3 (pl) * 2007-09-28 2014-07-31 Cyclacel Ltd Pochodne pirymidyny jako inhibitory kinaz białkowych

Also Published As

Publication number Publication date
WO2013144632A1 (en) 2013-10-03
US20150320762A1 (en) 2015-11-12
EP2833865A1 (en) 2015-02-11
JP2015514703A (ja) 2015-05-21

Similar Documents

Publication Publication Date Title
UA110259C2 (uk) Похідні піролопіримідину і пурину
EA201690752A1 (ru) Ингибиторы g12c kras
EA201590879A1 (ru) Арилконденсированные и гетероарилконденсированные лактамы
BR112022003165A2 (pt) Método de tratamento de cânceres associados a kras
MX381326B (es) Derivados de 7h-imidazo[1-5-a]pirazin-8-ona como inhibidores de la fosfodiesterasa 9(pde9); y el uso de los mismos en el tratamiento de trastornos neurodegenerativos
EA201391324A1 (ru) Бис(фторалкил)-1,4-бензодиазепиноновые соединения
MX337440B (es) Antagonistas de trpv4.
MY204421A (en) Pyruvate kinase activators for use in treating blood disorders
EA201792214A1 (ru) Соединения замещенного хиназолина
PE20121815A1 (es) Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6
AR080688A1 (es) Derivados de 2,3-dihidro-1h-inden-1-il-2,7-diazaspiro[3.5]nonano como agonistas o antagonistas inversos de grelina
EA201390766A1 (ru) БЕНЗОКСАЗЕПИНЫ КАК ИНГИБИТОРЫ PI3K/mTOR И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ И ПОЛУЧЕНИЯ
EA201270778A1 (ru) Бициклические гетероарильные аналоги в качестве модуляторов рецептора gpr119
MX2014006027A (es) Derivados de 2-fenilaminopirimidina como moduladores de proteina cinasa 2 rica en unidades repetitivas de leucina (lrrk2) para el tratamiento de la enfermedad de parkinson.
PE20110405A1 (es) Derivados de piridino-piridinonas como inhibidores de la actividad de la tirosina quinasa de pdgf-r y/o flt-3 y su preparacion
EA201491747A1 (ru) Замещенные пиридопиримидиновые соединения и их применение в качестве flt3 ингибиторов
EA201790713A1 (ru) N-АЛКИЛАРИЛ-5-ОКСОАРИЛОКТАГИДРОЦИКЛОПЕНТА[c]ПИРРОЛЬНЫЕ НЕГАТИВНЫЕ АЛОСТЕРИЧЕСКИЕ МОДУЛЯТОРЫ NR2B
PE20141553A1 (es) Compuestos de triazolopiridina como inhibidores de la ped10a
MY193754A (en) Treatment for parkinson's disease
RU2015150120A (ru) Соединение дикарбоновой кислоты
EA201391211A1 (ru) Новые соединения в качестве лигандов гистаминовых h-рецепторов
GB201205752D0 (en) Treatment
WO2012131656A3 (en) Compounds for use as therapeutic agents affecting p53 expression and/or activity
AR083832A1 (es) DERIVADOS DE TETRAHIDROPIRIDO[3,2-F][1,4]OXAZEPIN-8-AMINA PARA EL TRATAMIENTO DE ENFERMEDADES Ab-RELACIONADAS
AR091520A1 (es) Inhibidores piranopiridona de tanquirasa

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)